# Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy

> **NCT02582710** · PHASE3 · UNKNOWN · sponsor: **University Hospital, Strasbourg, France** · enrollment: 96 (estimated)

## Conditions studied

- Carotid Endarterectomy

## Interventions

- **DIETARY_SUPPLEMENT:** VASCAZEN
- **DIETARY_SUPPLEMENT:** PLACEBO

## Key facts

- **NCT ID:** NCT02582710
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582710, "Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02582710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*